V. Boccaccio

发表

HCV therapy and risk of liver cancer recurrence: who to treat?

M. Colombo, V. Boccaccio, 2018, Nature Reviews Gastroenterology & Hepatology.

Is the benefit of treating patients with cirrhosis proven?

P. Maisonneuve, M. Russo, S. Bruno, 2016, Liver international : official journal of the International Association for the Study of the Liver.

Treatment discontinuation with peg-interferon: what to consider

M. Russo, M. Carbone, S. Bruno, 2015, Expert review of clinical pharmacology.

Optimal management of patients with chronic hepatitis C and comorbidities

S. Bruno, V. Boccaccio, 2015, Liver international : official journal of the International Association for the Study of the Liver.

Management of HCV patients with cirrhosis with direct acting antivirals

S. Bruno, V. Boccaccio, 2014, Liver international : official journal of the International Association for the Study of the Liver.

Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals.

M. Colombo, P. Lampertico, A. Di Leo, 2019, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

The Circulating Level of Soluble Receptor for Advanced Glycation End Products Displays Different Patterns in Ulcerative Colitis and Crohn’s Disease: A Cross-Sectional Study

C. Falcone, A. Vanoli, G. Corazza, 2015, Digestive Diseases and Sciences.

Role of the advanced glycation end products receptor in Crohn's disease inflammation.

C. Falcone, A. Rossi, A. Vanoli, 2013, World journal of gastroenterology.

Validation of the Italian translation of the Inflammatory Bowel Disease Questionnaire.

G. Corazza, G. Porro, M. Russo, 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombopag studies.

E. Giannini, M. Russo, S. Bruno, 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon

A. Gasbarrini, M. Zoli, F. Piscaglia, 2017, Alimentary pharmacology & therapeutics.

Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.

P. Maisonneuve, G. Cabibbo, S. Bruno, 2016, Journal of hepatology.

Hepatitis C eradication with DAA and risk of liver cancer recurrence: The debate unrests

M. Colombo, V. Boccaccio, 2018, Journal of viral hepatitis.

P465 SVR IS ASSOCIATED WITH NO RISK REDUCTION OF HCC DEVELOPMENT IN PATIENTS WITH HCV-RELATED CIRRHOSIS. A PROSPECTIVE, UP-TO 23 YEARS, COHORT FOLLOW-UP STUDY

M. Mondelli, P. Maisonneuve, S. Bruno, 2014 .

SVR is associated with no risk reduction of HCC development in patients with HCV-related cirrhosis. A prospective, up-to 23 years, cohort follow-up study

P. Maisonneuve, S. Bruno, S. Rossi, 2014 .

Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus‐related cirrhosis who attained sustained virological response

P. Maisonneuve, G. Cabibbo, L. Giacomelli, 2017, Liver international : official journal of the International Association for the Study of the Liver.

High efficacy of direct‐acting anti‐viral agents in hepatitis C virus‐infected cirrhotic patients with successfully treated hepatocellular carcinoma

P. Lampertico, A. Di Leo, P. Maisonneuve, 2018, Alimentary pharmacology & therapeutics.

SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with DAAs: a prospective multi-centric Italian study

P. Lampertico, P. Maisonneuve, M. Brunetto, 2018 .

Impact of virus eradication in patients with compensated hepatitis C virus‐related cirrhosis: competing risks and multistate model

S. Bruno, S. Rossi, A. Craxì, 2016, Liver international : official journal of the International Association for the Study of the Liver.

Interferon lambda-3 is not associated with clinical outcome in patients with HCV-induced compensated cirrhosis: a long-term cohort study.

V. Vaira, P. Maisonneuve, S. Bruno, 2015, Antiviral research.